Guest Current Subscriptions | Open Access Plus | Free Content | About | Sign in | New Users: Sign up | Mark List  
  Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets - Inflammation & Allergy)

Volume 10 Issue 3
ISSN: 1871-5281

   All Titles

Biology of the Interleukin-9 Pathway and its Therapeutic Potential for the Treatment of Asthma
pp.180-186 (7) Authors: Chad K. Oh, Donald Raible, Gregory P. Geba, Nestor A. Molfino

Asthma is a complex disease characterized by variable airflow limitation, hyperresponsiveness, and airways inflammation. Despite valuable therapeutic advances to control asthma symptoms in the last decade, a quantifiable proportion of patients with moderate to severe asthma continue to experience inadequate disease control, highlighting an important unmet need. In animal models of asthma, interleukin (IL)-9 regulates the development of airway inflammation, mucus production, airway hyperresponsiveness, and airway fibrosis largely by increasing mast cell numbers and activity in the airways. Mast cells are involved in the pathogenesis of eosinophilic and noneosinophilic asthma. Thus, targeting the IL-9 pathway may provide a new therapeutic modality for asthma. The purpose of this review is to summarize the IL-9 mast cell axis in the pathogenesis of asthma and discuss clinical studies with a humanized anti IL-9 monoclonal antibody, MEDI-528, in subjects with asthma.

Keywords: Airways, asthma, mast cell, inflammation, interleukin-9, monoclonal antibody, hyperresponsiveness, Treatment of Asthma, IL-9 pathway, IL-9,
Affiliation: MedImmune, LLC, One MedImmune Way, Gaithersburg, MD 20878, USA.

  Key: New Content Free Content Open Access Plus Subscribed Content

Bentham Science Publishers

  Copyright © 1994 - 2015   Bentham Science Publishers